DRUG | TYPE OF STUDY | DETAILS | OUTCOMES |
---|---|---|---|
Psyllium | Surveillance | 100 > N < 199 during first trimester | No increased risk of malformations7 |
Docusate sodium | Prospective | N = 116 anytime during pregnancy | No increased risk of malformations8 |
Surveillance | N = 473 during first trimester | No increased risk of malformations (1/473 = 0.2%)7 | |
Surveillance | N = 319 during first trimester | No increased risk of malformations (3/319 = 0.9%)9 | |
Surveillance | N = 232 during first trimester | No increased risk of malformations (9/232 = 3.9%)10 | |
Lactulose | Pharmacokinetics | N = 6 adults given lactulose | Systemic bioavailability < 3%11 |
Polyethylene glycol | Pharmacokinetics | N = 11 adults given polyethylene glycol | Not absorbed12 |
Bisacodyl | Pharmacokinetics | N = 12 adults given oral and rectal bisacodyl | Minimal absorption13 |
Pharmacokinetics | N = 16 adults given bisacodyl suppository | Systemic bioavailability < 5%14 | |
Senna | Case-control | N = 506 cases (260 during first trimester) | No increased risk of malformations (OR 0.8; 95% CI 0.4–1.4) or adverse pregnancy outcomes15 |
Pharmacokinetics | N = 937 control (500 during first trimester); N = 10 adults given senna | Systemic bioavailability < 5%16 |
OR—odds ratio.
Data from Jick et al,7 Heinonen et al,8 Aselton et al,9 Briggs et al,10 Carulli et al,11 Wilkinson,12 Roth and Beschke,13 Flig et al,14 Acs et al,15 and Krumbiegel and Schulz.16